Omigapil

Drug Profile

Omigapil

Alternative Names: CGP 3466; CGP 3466 maleate; CGP 3466B; SNT 317; TCH 346

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Santhera Pharmaceuticals
  • Class Neuroprotectants; Oxepins; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Glyceraldehyde 3 phosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Muscular dystrophies
  • Discontinued Amyotrophic lateral sclerosis; Motor neuron disease; Parkinson's disease

Most Recent Events

  • 01 May 2016 Omigapil receives Fast Track designation for Muscular dystrophies [PO] (In adolescents, In children) in USA
  • 20 Jul 2015 Santhera completes enrolment in the phase I CALLISTO trial for Muscular dystrophies in children & adolescents in USA (NCT01805024)
  • 01 Dec 2014 Phase-I clinical trials in Muscular dystrophies (In adolescents, In children) in USA (PO) (NCT01805024)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top